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Background: Respiratory failure is the most common cause of morbidity and mortality in
patients with neuromuscular diseases (NMD). Non-invasive mechanical ventilation is consid-
ered highly effective for treating chronic respiratory failure. Perception and knowledge of risks
associated with respiratory derangements may be underestimated.
Objective: The aim of our study was to evaluate the association among respiratory function,
general clinical disability and need of home mechanical ventilation (HMV) in patients with
slowly progressive NMD admitted for the first time to dedicated respiratory outpatient clinics.
Methods: Anthropometrics, lung function, respiratory muscle function, daytime blood gases
data, and general clinical disability assessed by means of a clinical interview were recorded.
Indication for HMV was an arterial CO2 tension >45 mmHg and/or a vital capacity <50% pre-
dicted, and/or maximal inspiratory pressure <60 cmH2O.
Results: Two out of 5 patients complained of dyspnoea during daily activity and dysphagia,
while more than 1/3 had ineffective cough and speech difficulties. Two-third of the whole
group were considered to need HMV. By applying one or more criteria for NMD diagnosis, great
variability was found for indication to HMV. Clinical disability was inversely related to dynamicses; ALS, amyotrophic lateral sclerosis; BMI, body mass index; DMD, Duchenne muscular dystrophy;
expiratory volume in one second; FIM, functional independence measure; FVC, forced vital capacity;
HMV, home mechanical ventilation; MIP, maximal inspiratory pressure; MEP, maximal expiratory
al ventilation; NMD, neuromuscular diseases; OT, all other diagnosis; % pred, percentage of the
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152 D. Fiorenza et al.and static lung volumes, and to respiratory muscle function.
Conclusions: About two-third of NMD patients admitted to a respiratory clinic is a candidate for
home mechanical ventilation being their clinical derangement inversely related with respira-
tory function. The use of a simple dedicated clinical disability interview may reduce underes-
timation of HMV need.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Most neuromuscular diseases (NMDs) are characterised by
progressive muscular impairment leading to loss of ambula-
tion, wheelchair-bound, swallowing difficulties, respiratory
muscle weakness, and eventually death from respiratory
failure.1e3 Neuromuscular diseases can bedivided into rapidly
and slowly progressive: there is no accepted definition of
these subgroups but understanding the speed of progression
of the disease is important in deciding the appropriateness of
non-invasive mechanical ventilation (NIV).4 Rapidly progres-
sive NMD are characterised by monthly worsening of muscle
impairment and death in few years as it occurs in amyotrophic
lateral sclerosis (ALS) and spinal muscular atrophies type 1
(SMA-1). Relatively rapid progression is also observed in
Duchenne muscular dystrophy (DMD). Other myopathies like
Becker muscular dystrophy, Facioscapulohumeral muscular
dystrophy, limb girdle muscular dystrophy, and myotonic
dystrophy, usually result in a slowly progressive reduc-
tion in muscular function and only mildly reduced life
expectancy.1e3
Respiratory failure is themost commoncause ofmorbidity
and mortality in patients with chronic or rapidly progressive
NMD.5 Reduction in respiratory muscles strength with inef-
fective alveolar ventilation and difficult airway secretions
clearance may lead to chronic respiratory insufficiency (CRI)
and potentially life-threatening problems.5 However, while
it iswell recognised that NMDare related to an impairment of
motor ability, perception and knowledge of the risks associ-
ated with respiratory function impairment are scanty.
Dyspnoea usually appears late in the natural history of the
disease, thus earlymonitoring of lung and respiratorymuscle
functions should be mandatory and is considered the best
prognostic indicator in these patients.5e7
Non-invasive mechanical ventilation has been increas-
ingly used as an aid to treat CRI following respiratory
muscle impairment in patients with NMD.8,9 Most often NIV
is intermittently used life-long as home mechanical venti-
lation (HMV).8e10 Non-invasive mechanical ventilation has
been shown to improve respiratory function, sleep quality,
health-related quality of life and expanded life span both in
children and adult patients with NMD.8e10
Current guidelines give indications when to start HMV for
all different neuromuscular disorders independently of the
type of the underlying disease, although the different disor-
ders leading to CRI are suggested being substantially different
regarding disease course, symptom presentation, type of
skeletal muscle involvement and prognosis.10 Accordingly,
there is still uncertainty when to start HMV. A previous study
showed that blood gases and lung function parameters vary
substantially between patients with differing underlying NMD
when commenced onHMV.11 By contrast, maximal inspiratorypressure seems equally reduced in all patients and more
severely reduced compared with consensus guidelines.11
The aim of our study was to highlight the association
among respiratory function, general clinical disability and
HMV need in patients with slowly progressive NMD admitted
for the first time to a dedicated respiratory outpatient clinic.
Materials and methods
The study was conducted in accordance with the Declara-
tion of Helsinki. The Ethics Committees of all participating
centers approved the protocol and all patients signed the
informed consent.
Setting
The study was conducted in two dedicated respiratory
outpatient clinics [Pulmonary Rehabilitation Unit, Salvatore
Maugeri Foundation IRCCS, Medical Center of Lumezzane
(Brescia-Italy) and Pulmonary Unit, Cardio-Thoracic
Department, University Hospital of Pisa, Italy].
Study population
We recruited all consecutive NMD patients referred for
the first time to our clinics between June 2001 and
February 2005. Diagnosis was based on: (a) peripheral
muscle biopsy, (b) clinical examination and electromyog-
raphy (EMG), and/or (c) laboratory values. Patients were
referred to the respiratory clinics by general practitioners,
pediatricians, neurological centers where diagnosis had
been ascertained and by local associations of patients and
their caregivers (UILDM e Unione Italiana Lotta alla Dis-
trofia Muscolare: Italian Union for Muscular Dystrophy) in
a program of dedicated outpatient lung function follow-up
screening. Patients with cognitive problems, inability to
perform lung function test, diagnosis of rapidly progressive
NMD (ALS, SMA) were excluded from the study.
Types and times of examinations
Anthropometrics
Age, height, weight and nutritional status as assessed by
Body Mass Index (BMI) were recorded. In wheelchair-bound
patients, height was measured or estimated from arm span
from finger tip to finger tip.12
Daytime blood gases
Arterial blood gases (ABGs) were assessed by automated
analysers (EGA system; Ciba Corning, Rome, Italy) on blood
samples drawn from the radial artery while patient was
breathing room air for at least 1 h.
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Dynamic lung volumes and flow volume loops were assessed
by mass flow sensors with volume integration ( _Vmax; Sen-
sorMedics; Yorba Linda, CA; and Master Scope; Jaeger;
Hockberg, Germany) with the patients in the seated posi-
tion. The highest values of vital capacity (VC), forced VC
(FVC) and forced expiratory volume in one second (FEV1)
recorded in three different tests were considered and
expressed as percentage of the predicted values (% pred) as
described by Quanjer et al.13
Respiratory muscle function
Maximal inspiratory (MIP)andexpiratory (MEP)pressureswere
measured at residual volume and total lung capacity,
respectively using a respiratory module system (Sensor
Medics, Yorba Linda, CA, USA). Predicted valueswere as those
by Bruschi et al.14 MIP was obtained by coaching the patients
to breath tidally and, after a few normal breaths, to exhale as
far as possible before inspiring against the occluded airway as
strong and as long as possible. For measuring MEP after a few
normal breaths, patients were coached to take a deep breath
before expiring as strongly as possible. Participants were
instructed to exert maximal inspiratory and expiratory effort
during each measurement to maintain pressure level for at
least two seconds. Five consecutive efforts were recorded
allowing a 1-minute pause between each effort until two
reproducible maximal values were obtained. The best value
was retained for analysis and the mean value that could be
maintained for one second was calculated.15
General clinical disability
The general clinical disability state (GD) was assessed by
a clinical interview performed by physicians, nurses,
respiratory therapists, patients and caregivers, exploring (i)
general health status, (ii) dyspnoea during daily activity,
(iii) ability to speak, (iv) ability to cough, and (v) dysphagia.
A score was assigned to each item according to the level of
disability. The total score ranged from 5 to 33 (with 5 as the
best and 33 the worst score) and identified five classes of
disability: (1) no disabilities (range 5e6), slight (range
7e12), moderate (range 13e17), heavy (range 17e24) and
very heavy disability (range 24e33). Appendix 1 details the
items developed for the clinical interview which was per-
formed by a physician involved in the patient care
throughout a face-to-face meeting. The preliminary draft
of the interview was firstly tested by the focus group of
specialists of the Respiratory Unit of Pisa to assess read-
ability and clarity. Thereafter, 30 patients meeting the
inclusion criteria for the study, and their families, were
requested to provide their comments, changes and
suggestions.
In a group of patients, the overall disability according to
the functional independence measure (FIM), an interna-
tional standard measurement of disability, was measured as
well. The main element of evaluation is a questionnaire
considering 18 daily living activities (13 sphincter and
mobility, 5 cognitive). Each activity can receive a score
ranging from 1 (complete dependence on others) to 7
(complete independence). The cumulative scores produce
a quantitative index of person disability.16
When patients were found possible candidate for
HMV according to a paCO2 >45 mmHg, VC <50% pred, MIP<60 cmH2O
5,8,10,17 with or without clinical symptoms they
were invited to undergo immediate or urgent NIV adapta-
tion after an inpatient nocturnal hypoventilation moni-
toring with saturimetric or polisomnographic tracing.
Statistical analysis
All the data were expressed as mean SD. To test differ-
ences in lung function tests and disability, all patients were
divided into two groups according to the admission diagnosis:
(a) DMD and(b) all other diagnosis (OT). Statistical analysis
was performed using SPSS software (release 12.0, SPSS;
Chicago, IL). A 2-sample t-test was used for comparison of
results between DMD and OT groups and between the 61
patients submitted to HMV and 34 patients submitted only to
a respiratory follow up. Spearman’s rank correlation was
used to test and indicate the relationships between the
respiratory functional data and disability score. The number
of patients presenting dyspnoea, difficulty in cough or
speech and dysphagia, according to a disability score 2 for
each of the five sub-items, was also recorded. Percentage of
patients to be considered as candidate for HMV according to
one, two or three combined criteria data were also tested.
p-Values <0.05 were considered significant.
Results
During the study period, 210 patients were admitted for the
first time to our respiratory clinics: 2 patients were excluded
due to cognitive problems, 8 for inability to perform lung
function tests, 2 refused to participate, 11 had instable
disease or recent drug change, 1 patient was participating to
a drug clinical trial, 91 hadALS. Therefore,weenrolled in the
study 95 patients: 24 had DMD while 71 other NMD (Table 1).
No patients were on long-term oxygen therapy.
Anthropometrics
There were no differences between the two groups of
patients in anthropometric and clinical/functional data
(Table 2). Only age and height were significantly different
between groups.
Daytime blood gases
Although mean ABGs were normal, about 20% of all patients
were hypercapnic, independent of diagnosis (Table 2).
Lung function
No statistical difference between groups was found in
clinical and lung function data, although the percentage of
patients with VC <50% predicted was double in DMD
compared to OT (Table 2).
Respiratory muscle function
Despite no significant differences in MIP values between
groups (pZ 0.068), about a half of the patients, either DMD
or OT, showed a reduction of the strength of inspiratory
muscles.
Table 1 Patients’ diagnosis (both enrolled and excluded).
Diagnosis #
Enrolled patients 95
Duchenne muscular dystrophy 24
Other neuromuscular diseases 71
Steinert 35
Limb girdle 8
Miastenia Gravis 2
Spinal amyotrophy 6
Facioscapulohumeral muscular dystrophy 9
Others 11
Excluded patients 115
Duchenne muscular dystrophy 7
Other neuromuscular diseases 108
Steinert 6
Miastenia gravis 2
Spinal amyotrophy 2
Amyothrophic lateral sclerosis 91
Others 7
Table 2 Anthropometric, clinical, respiratory function data an
Total (nZ 95)
Age (years) 41.8 17.36
Height (cm) 164.2 10.95
Weight (kg) 66.0 19.30
BMI (Kg/m2) 24.89 6.41
paO2 (mmHg) 86.49 12.23
paCO2 (mmHg) 39.13 5.96
paCO2 >45 mmHg (n, %) 47.55 2.23 (18,19)
paCO2 <45 mmHg (n, %) 36.97 4.5 (77, 81)
pH 7.41 0.03
VC (l) 2.80 1.35
VC (% predicted) 75.49 28.99
VC >50% predicted (n, %) 86.02 20.15 (77, 81)
VC <50% predicted (n, %) 30.44 13.39 (18.19)
FEV1 (l) 2.35 1.13
FEV1 (% predicted) 76.57 29.71
MIP (cmH2O) 53.87 26.67
MIP >60 cmH2O (n, %) 79.05 19.90 (45,47)
MIP <60 cmH2O (n, %) 36.24 14.19 (50, 53)
MEP (cmH2O) 63.41 35.20
Disability Scale (total) 8.58 3.26
Health 2.38 1.52
Dyspnoea 1.56 0.80
Ability to speak 1.49 0.94
Cough 1.63 1.00
Dysphagia 1.51 0.75
FIM scalea (n) 89.14 27.25 (28)
BMI, body mass index; DMD, Duchenne muscular dystrophy; FEV1, fo
pendence measure; MEP, maximal expiratory pressures; MIP, maxima
paO2, arterial partial pressure of oxygen; paCO2, arterial partial pres
a Available for 28 patients.
b p< 0.001 DMD vs. OT.
c p< 0.05 DMD vs. OT.
154 D. Fiorenza et al.General clinical disability
The total average disability score showed a slight degree of
general disability (8.58 3.26). According to the interview:
(a) dyspnoea during the activity of the daily life was found
in 39 out of 95 patients (41.1%) (37.5% DMD and 42.3% of OT,
respectively), (b) 35.8% (34/95) of patients had difficulties
to swallow (DMD and OT showed dysphagia in 33.3% and
36.6%, respectively), (c) difficulty in speech was present in
29.5% (28/95) of patients (25.0% of DMD and 31.0% OT,
respectively), and (d) reduction in cough ability was found
in 35/95 patients (36.8%) (45.8% of DMD and 33.8% of OT,
respectively). Table 3 shows correlations between specific
disability sub-items and lung function. Total clinical
disability was inversely related with VC, FEV1 and with MIP
and MEP. In details, specific disability sub-items as speech
and cough ability confirms these results being inversely
related with VC, FEV1, MIP and MEP. Dysphagia was
inversely related with MIP. The average overall disability
measured with the Functional Independence Measure score
showed a moderate level of impairment with only 3
patients with very severe disability; no differences were
found according to different studied NM diseases.d disability score in the studied populations
DMD (nZ 24) OT (nZ 71)
27.83 15.58b 46.67 15.25b
162.71 11.39b 164.75 10.82b
57.46 19.36 68.89 18.54
22.48 6.64 25.75 6.10
90.11 8.75 85.50 12.90
40.35 5.68 38.80 6.03
48.82 3.3 (4, 17) 47.19 1.83 (14, 18)
38.10 3.64 (20, 83) 36.66 4.69 (57, 80)
7.41 0.02 7.41 0.03
2.86 1.80 2.78 1.17
69.25 35.52 77.61 26.38
85.33 23.27 (18, 75) 86.23 19.32 (59, 83)
21.0 15.42 (6.25)c 35.16 9.79 (12.17)c
2.38 1.52 2.34 1.00
69.91 36.85 78.63 27.11
55.15 32.66 53.48 24.82
88.12 20.47 (12,50) 76.37 17.92 (33,46)
33.16 16.05 (12, 50) 37.21 13.64 (38, 54)
74.35 52.30 60.05 27.67
9.21 4.35 8.37 2.80
2.88 2.29 2.21 1.13
1.58 0.92 1.55 0.77
1.46 0.93 1.51 0.95
1.79 1.06 1.58 0.98
1.42 0.65 1.54 0.79
94.31 27.61 (16) 82.25 26.30 (12)
rced expiratory volume in the first second; FIM, functional inde-
l inspiratory pressure; ns, not significant; OT, all other diagnosis;
sure of carbon dioxide; and VC, vital capacity.
Table 3 Spearman’s rank correlations between specific disability sub-items and respiratory function.
paCO2 (mmHg) VC (%) FEV1 (%) MIP (cmH2O) MEP (cmH2O) Health Dyspnoea Speech Cough Dysphagya Tot DS
paCO2 (mmhg) rho 0.125 0.163 0.160 0.002 0.075 0.031 0.032 0.007 0.065 0.017
p 0.245 0.129 0.153 0.989 0.488 0.772 0.770 0.950 0.549 0.877
VC (%) rho 0.125 0.940(**) 0.365(**) 0.381(**) 0.017 0.040 0.108 0.387(**) 0.111 0.219(*)
p 0.245 0.01 0.01 0.001 0.867 0.697 0.297 0.001 0.284 0.033
FEV1 (%) rho 0.163 0.940(**) 0.378(**) 0.367(**) 0.065 0.090 0.116 0.404(**) 0.076 0.244(*)
p 0.129 0.01 0.01 0.001 0.537 0.388 0.268 0.001 0.471 0.018
MIP (cmH2O) rho 0.160 0.365(**) 0.378(**) 0.688(**) 0.007 0.091 0.288(**) 0.351(**) 0.242(*) 0.317(**)
p 0.153 0.01 0.01 0.01 0.946 0.407 0.008 0.001 0.026 0.003
MEP (cmH2O) rho 0.002 0.381(**) 0.367(**) 0.688(**) 0.012 0.052 0.284(**) 0.414(**) 0.150 0.214(*)
p 0.989 0.01 0.01 0.01 0.913 0.639 0.008 0.01 0.171 0.050
Health rho 0.075 0.017 0.065 0.007 0.012 0.416(**) 0.309(**) 0.217(*) 0.056 0.669(**)
p 0.488 0.867 0.537 0.946 0.913 0.01 0.002 0.035 0.590 0.01
Dyspnoea rho 0.031 0.040 0.090 0.091 0.052 0.416(**) 0.410(**) 0.008 0.191 0.584(**)
p 0.772 0.697 0.388 0.407 0.639 0.001 0.01 0.942 0.064 0.01
Speech rho 0.032 0.108 0.116 0.288(**) 0.284(**) 0.309** 0.410(**) 0.383(**) 0.345(**) 0.642(**)
p 0.770 0.297 0.268 0.008 0.008 0.002 0.01 0.01 0.001 0.001
Cough rho 0.007 0.387(**) 0.404(**) 0.351(**) 0.414(**) 0.217(*) 0.008 0.383(**) 0.234(*) 0.520(**)
p 0.950 0.01 0.01 0.001 0.01 0.035 0.942 0.01 0.022 0.01
Dysphagya rho 0.065 0.111 0.076 0.242(*) 0.150 0.056 0.191 0.345(**) 0.234(*) 0.522(**)
p 0.549 0.284 0.471 0.026 0.171 0.590 0.064 0.01 0.022 0.01
Tot DS rho 0.17 0.219(*) 0.244(*) 0.317(**) 0.214(*) 0.669(**) 0.584(**) 0.642(**) 0.520(**) 0.522(**)
p 0.877 0.133 0.018 0.003 0.050 0.01 0.01 0.01 0.01 0.001
FEV1, forced expiratory volume in the first second; MEP, maximal expiratory pressures; MIP, maximal inspiratory pressure; paCO2, arterial partial pressure of carbon dioxide; paO2, arterial
partial pressure of oxygen; Tot Ds, total disability scale score; VC, vital capacity. **Significant correlation at the 0.01 level (2-tailed); *significant Correlation at the 0.05 level (2-tailed).
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156 D. Fiorenza et al.Home mechanical ventilation
Table 4 shows the proportion of patients to be considered
as candidate for HMV according to one, two or three
combined criteria. Both groups shared a low MIP as a HMV
indication, whereas hypercapnia and a low VC were single
indications for OT and DMD, respectively. Table 4 shows
that combining two or three HMV indication criteria, the
rate of capturing HMV indication decreases. This prescrip-
tion criterion was able to capture more frequently patients
with DMD rather than OT. Sixty-one (64.2%) patients met at
least one criterion. These 61 patients presented different
isolated or combined clinical symptoms: 39 presented
dyspnoea or orthopnea during activity of daily life, 18
morning headache, 27 daytime hypersomnolence, 17 sleep
disturbed by frequent awakenings while 7 patients did not
presented any symptoms. Four patients were immediately
submitted to NIV adaptation, 57 patients were ventilated
within one month after a nocturnal hypoventilation moni-
toring with saturimetric (44 subjects) or polisomnographic
tracing (13 subjects). The remaining 34 patients not
proposed for ventilation were inserted in a structured
follow up according to disease and functional data.
These 34 patients, when compared to the 61 patients
submitted to HMV, presented an higher level of VC
(89 3.4% vs. 66 4% of predicted p< 0.0004) and MIP
(85 12 vs. 41 3 cmH2O p< 0.0001) with a lower level of
paCO2 (37 0.84 vs. 41 0.83 mmHg p< 0.01) and general
clinical disability score (7.5 0.40 vs. 9.2 0.45 p< 0.01).
Discussion
About 40% of NMD patients at first admission to a respiratory
clinic complained of dyspnoea during their daily activities
and showed risk of dysphagia, whereas more than 1/3 had
ineffective cough and speech difficulties; about two-third
of the whole group could be candidate for HMV. However,
according to more criteria and specific NMD diagnosis, great
variability was found in indications for HMV. As expected,Table 4 Patients to be considered as candidate for HMV accord
DMD
Patients enrolled in the study, n 24
Pts with MIP <60 cmH2O, n (%) 12 (50.0
Pts with paCO2 >45 mmHg, n (%) 4 (16.6
Pts with VC <50% pred, n (%) 6 (25.0
Patients with at least one criterium,
n (%)
13 (54.2
Pts with MIP <60 cmH2Oþ paCO2
>45 mmHg, n (%)
3 (12.5
Pts with MIP <60 cmH2Oþ VC <50%
pred, n (%)
5 (20.8
Pts with paCO2 >45 mmHgþ VC
<50% pred, n (%)
4 (16.6
Pts with MIP <60 cmH2Oþ paCO2
>45 mmHgþ VC <50% pred, n (%)
2 (8.3)
DMD, Duchenne muscular dystrophy; MIP, maximal inspiratory pressure
dioxide; % pred, percentage of the predicted values; and VC, vital caclinical disability was inversely related to respiratory
function. The use of a simple dedicated clinical disability
interview may reduce underestimation of HMV need.
The main novelty of our study, performed in a larger
sample size when compared to previous studies, is real life
picture while monitoring lung function and general disability
in patients with NMD admitted for the first time to a dedi-
cated respiratory outpatient clinic: correlation between
disability and respiratory function with risk of underestima-
tion and delay to initiate HMV may be frequent.
NMD are progressive conditions leading to respiratory
failure and severe disability. Therefore, a close clinical
follow-up and a systematic evaluation of lung function and
general/respiratory disability are mandatory. When respi-
ratory disability and strength of respiratory muscles
decrease, it is imperative to consider specific therapies
such as home NIV and airway clearance techniques.17e19
Several functional and clinical respiratory measures
have been routinely used for the evaluation of patients with
NMD by measuring VC, MIP and MEP.11,20 VC is doubtfully
related to inspiratory muscle function and it has been
proposed as an indicator for evaluation of disease
progression.21 However, in patients with NMD, VC may be
a late predictor of disease progression when compared to
respiratory muscle function.22 Increased carbon dioxide
retention has been associated with a reduction of >20%
pred FEV1.
23 Other lung function and non-invasive volitional
and non-volitional respiratory muscle tests have been
recently proposed in children with NMD.10,24 Our study
confirms both the severe functional impairment of the
respiratory muscle function and the loss in VC. Dreher11
found that mean FVC at HMV onset was 40.3 17.5% pre-
dicted in all patients being > 50% predicted in eight
patients (12%) whereas maximal inspiratory mouth occlu-
sion pressure was compromised in all patients and lower
when compared with international consensus guidelines.10
Also in our sample size the MIP value for in patients
candidate to HMV was severely compromised in more than
50% of the cases. Global inspiratory muscle strength was
similarly impaired in patients with different NMD, whereasing to MIP, paCO2 and VC.
OT Total
71 95
) 38 (53.5) 50 (52.6)
) 14 (19.7) 18 (18.9)
) 12 (16.9) 18 (18.9)
) 48 (67.6) 61 (64.2)
) 7 (9.85) 10 (10.5)
) 8 (11.3) 13 (13.7)
) 3 (4.2) 7 (7.4)
2 (2.8) 4 (4.2)
; OT, all other diagnosis; paCO2, arterial partial pressure of carbon
pacity.
NMD patients at first admission to a respiratory outpatient clinic 157significant differences in hypercapnia and VC were found.
These findings are in line with other studies4,11 and may
indicate that impairments of inspiratory muscle strength
rather than hypercapnia or reduced lung function trigger
the respiratory symptoms of patients with neuromuscular
disorders.
Moreover, the use of single tests such as spirometry,
ABGs or respiratory muscle function might over- or under-
diagnose chronic respiratory weakness and failure. The
availability of multiple tests of respiratory function
increases diagnostic precision and facilitates the decision
process.
Despite guidelines for HMV in patients with NMD,20 clear
suggestions on the optimal frequency of visits and on how
to follow-up respiratory function and disability problems
are lacking. When we looked at the single indication for
HMV, hypercapnia was more indicative for the OT group. At
the same way, the whole group of patients with DMD had
a higher, although not statistically significant, impairment
in VC, whereas a low MIP value appeared as a common
indication to start HMV. Moreover, our results indicated
that combination of different respiratory function tests
reduce decision rate to start HMV: the risk of over-or under-
prescription of HMV in NMD chronic respiratory weakness
appears clear.
The three most frequent problems of patients with NMD
are muscle weakness, difficulty in exercising and fatigue,
all leading to reduced physical activity and increasingly
sedentary daily life. The use of a disability scale is an
important tool for evaluating the fainting patient. The
disability scales in NMD study mainly focus on physical
activity25 and motor deficit.26 Therefore, these scales
highlight the severity of the disease and its progression
investigating the overall autonomy for walking and non-
walking patients by studying the head, the trunk, and the
upper and lower limbs. However, respiratory muscle func-
tions are not considered.
To this end, our results underline the important rela-
tionship between clinical general disability and respiratory
function; as expected, two important bulbar functions such
as speech and cough were found to have the greatest
relationship with respiratory function indexes. Our dedi-
cated outpatient clinics follow-up patients with NMD by
regularly performing lung function tests and a simple
interview. This latter could be used also by not specialised
personnel as general practitioners, pediatricians or nurses.
Thus, the above mentioned approach provided us with
a more accurate indication for starting HMV and respiratory
cough assistance programs.Conclusions
A significant group of patients with NMD at first admission to
respiratory clinic may present severe clinical derangement
inversely related with respiratory function. About two-third
could be candidate for immediate or urgent home
mechanical ventilation. At difference with suggestions of
current guidelines, we found a risky underestimation and
thus a delay in the respiratory evaluation in the real life.
The use of a simple dedicated clinical disability interview
may reduce underestimation of HMV need.Acknowledgment
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